Rapid aging of the population, greater access to healthcare in emerging markets and advances in science create opportunities to enhance the lives of patients through innovation.
Healthcare innovation generally refers to the drug discovery and development process – the translation of fundamental science into new drugs, vaccines and devices. This type of innovation requires significant investment and teams commanding specialized, yet complementary, skills.
Our strategy of focused diversification helps us to capitalize on this changing healthcare environment while balancing risk. Novartis has leading businesses in science-based, fast growing segments of healthcare.
Novartis aims to change the practice of medicine, and innovation at Novartis not only means developing effective, targeted medicines quickly, but also ensuring that these medicines get to the patients who need them.
Novartis strives to ensure that patients can benefit from new and effective drugs as quickly as possible by:
Prioritizing our research efforts based on sound science and patient need
Leveraging our core research and development capabilities across all divisions to continue building our pipeline of innovative pharmaceuticals; eye care treatments; affordable, high-quality generics; consumer health products and vaccines
Shifting to a more integrated approach, working together with physicians and our customers to optimize patient outcomes
Identifying biomarkers to develop high-quality companion diagnostics in support of our medicines across all therapeutic areas
Carefully designing clinical trials to generate data that helps governments measure the economic benefits of new medicines
Collaborating with governments globally to create innovative pricing arrangements
Investing in forward-looking digital technologies that improve patient outcomes
The success of this strategy is evident in our long-established track record of research productivity.